Skip to content
Review

Artificial intelligence and CRISPR-based approaches for targeted delivery of bacteriophages.

Jul 2026 · International journal of pharmaceutics · Vol 701, pp. 127155 · 0 citations · 127 references
Medicine

TL;DR

A systematic overview of bacteriophage biology, life cycle, and mechanisms of action is provided, highlighting the influence of phage morphology on therapeutic performance, recent advances, current clinical and preclinical studies, and future perspectives.

Abstract

The rapid emergence of multidrug-resistant (MDR) bacteria has increased interest in bacteriophage therapy as a promising alternative to conventional antibiotics. Bacteriophages are host-specific bacterial viruses that selectively infect and destroy pathogenic bacterial strains. Recent developments in artificial intelligence (AI) and CRISPR-based technologies offer innovative approaches to address challenges such as narrow host range, rapid immune clearance, phage instability, bacterial resistance, and biofilm penetration barriers. By integrating AI-driven structural modeling with CRISPR-mediated genome editing, these methods enable the targeted delivery of bacteriophages. This review focuses on next-generation approaches that combine AI-assisted phage identification, host prediction, and therapeutic optimization with CRISPR-based genome engineering for targeted phage delivery and improved safety. Overall, this review highlights the potential of AI- and CRISPR-assisted phage therapy for the treatment of MDR bacterial infections. This review provides a systematic overview of bacteriophage biology, life cycle, and mechanisms of action, highlighting the influence of phage morphology on therapeutic performance, recent advances, current clinical and preclinical studies, and future perspectives. Although phage therapy shows considerable potential against MDR bacterial infections, several challenges related to delivery, safety, and clinical translation remain. The integration of AI and CRISPR technologies may improve phage selection, targeting specificity, and therapeutic performance. Continued research, clinical validation, and regulatory development will be essential for translating these advances into practical antimicrobial therapies.

View source

Similar papers

Review Aug 2026

Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria

This review critically examines bacteriophage-based antimicrobials, CRISPR-Cas therapeutic systems, and their emerging integration as CRISPR-armed phages, highlighting their comparative advantages, current limitations, and future potential as promising targeted antimicrobial approach platforms requiring further clinica...

Anjaneyulu Musini, V. Yata, Sarad Pawar Naik Bukke et al. · 0 citations
Review Open access Aug 2026

Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections

The increasing clinical evidence shows that synthetic biology can effectively overcome the inherent defects of natural bacteriophages, confirming the safety and initial efficacy of bacteriophage therapy.

Xuan Wang, Haolin Zhou, T. S. Lim et al. · 0 citations
Review Aug 2026

Bacteriophage Therapy as a Promising Substitute for Antibiotics: Current Advances, Clinical Applications, and Future Perspectives

Accumulating experimental and clinical evidence indicates that bacteriophage therapy could become an important component of future antimicrobial strategies, and Continued multidisciplinary research, standardized clinical protocols, and well-designed randomized clinical trials are essential to establish its long-term ef...

Himadri Sharma · 0 citations
Review Aug 2026

CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria

This study investigates the CRISPR-Cas framework’s potential as a cutting-edge tactic to fight antimicrobial resistance, and finds that the efficiency of CRISPR-Cas is diminished in some bacterial strains due to variations in their CRISPR loci.

Akmal Zubair, M. Hemal, Alaeldeen Ahmed et al. · 0 citations
Review Open access Jul 2026

CRISPR-ENABLED ANTIMICROBIAL STRATEGIES: REDEFINING PRECISION THERAPY AGAINST MULTIDRUG RESISTANT PATHOGENS

Overall, CRISPR-based antimicrobial therapy represents a transformative approach to precision infectious disease management, with continued technological innovation, interdisciplinary collaboration, and robust clinical validation expected to facilitate its safe, effective, and clinically accessible implementation again...

Dipankar Mukhopadhyay, Dr. Shilanjali Bhalerao, Dr. Vijayendra Gautam et al. · 0 citations
Review Open access Aug 2026

The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions

This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneo...

Sheng-Ting Zhang, Hui-Li Tao, Sha Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.